VRF Eye Specialty Group PLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$71,674	6
2021	Research	$131,347	17
2020	Research	$230,075	25
2019	Research	$161,820	24

Breakdown

Who paid Research payments · program years 2019–2022

Allergan Inc. $576,409 69 payments
EyePoint Pharmaceuticals US, Inc. $13,500 1 payment
Bausch Health US, LLC $3,400 1 payment
Shire North American Group Inc $1,608 1 payment

Studies the money was for Research payments · program years 2019–2022

A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $285,863 21 payments
A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $159,978 14 payments
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $57,971 14 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $48,743 13 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $17,846 6 payments
DEXYCU Retrospective study $13,500 1 payment
Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $6,008 1 payment
Retrospective Assessment of Latanoprostene Bunod Ophthalmic Solution 0.024 in Patients Newly Diagnosed with Open Angle Glaucoma or Ocular Hypertension $3,400 1 payment
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis $1,608 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.